THSD7A and nephrotic syndrome: Following a relapse of nephrotic syndrome in May 2021 (ACR 5 g/g, serum albumin concentration of 22 g/L, serum creatinine level of 168 μmol/L, anti-PLA2R at 249 IU/mL, and anti-THSD7A negative), anti-rituximab antibodies were monitored and found to be negative.